Ticker Details
ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.
IPO Date:	June 1, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.52B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 3.00%
Avg Daily Range (30 D):	$0.37 | 1.62%
Avg Daily Range (90 D):	$0.42 | 1.92%

Institutional Daily Volume
Avg Daily Volume:	1.22M
Avg Daily Volume (30 D):	1.13M
Avg Daily Volume (90 D):	1.3M

Trade Size
Avg Trade Size (Sh.):	125
Avg Trade Size (Sh.) (30 D):	59
Avg Trade Size (Sh.) (90 D):	60

Institutional Trades
Total Institutional Trades:	10,430
Avg Institutional Trade:	$2.36M
Avg Institutional Trade (30 D):	$4.27M
Avg Institutional Trade (90 D):	$4.37M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$4.35M
Avg Closing Trade (30 D):	$8.67M
Avg Closing Trade (90 D):	$8.13M
Avg Closing Volume:	181.48K

News

Jun 26, 2026 @ 4:17 PM Why Acadia Pharmaceuticals Stock Is Soaring Today Source: James Brumley

Dec 4, 2025 @ 12:12 AM Acadia Stock Up 59% in a Year — Is a $51 Mi... Source: Jonathan Ponciano

Sep 11, 2025 @ 3:30 AM Questex’s Fierce Pharma Announces the 2025 ... Source: Linda Lam

Apr 22, 2025 @ 5:00 PM Parkinson’s Disease Therapeutic Domain Proj... Source: Delveinsight

Feb 11, 2025 @ 8:48 AM Neuroregeneration Therapy Market to Surpass USD 64... Source: Transparency Market Research

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$2.23	$.02	$1.62
Diluted EPS	$2.21	$.02	$1.61
Revenue	$1.1B	$268.06M	$283.99M
Gross Profit	$1B	$243.27M	$257.76M
Net Income / Loss	$375.65M	$3.64M	$273.57M
Operating Income / Loss	$80.91M	$-4.62M	$17.39M
Cost of Revenue	$93.4M	$24.79M	$26.23M
Net Cash Flow	$63.54M	$104.49M	$-81.93M
PE Ratio